RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams maintains a Sector Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX) but lowers the price target from $431 to $425.
October 04, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
RBC Capital has maintained its Sector Perform rating on Vertex Pharmaceuticals but has lowered the price target from $431 to $425, indicating a slightly less optimistic outlook.
The lowering of the price target by RBC Capital suggests a slightly less optimistic view on Vertex Pharmaceuticals' future performance, which could lead to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100